%0 Journal Article
%A Portuguese, Andrew J.
%A Fang, Min
%A Tuazon, Sherilyn A.
%A Pont, Margot
%A Qu, Xiaoyu
%A Shasha, Carolyn
%A Comstock, Melissa
%A Lyons, Justina
%A Cole, Gabriel
%A Newell, Evan W.
%A Glynn, Emily
%A Soma, Lorinda A.
%A Green, Damian J.
%T Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma
%B Blood Advances
%D 2023
%R 10.1182/bloodadvances.2023011295
%J Blood Advances
%V 7
%N 23
%P 7235-7238
%@ 2473-9529
%X TO THE EDITOR:Anti-CD38 monoclonal antibodies (mAbs) are approved for multiple myeloma (MM) in the first-line and relapsed/refractory settings.1,2 Resistance portends a poor prognosis, yet underlying mechanisms have not been well characterized.3 Despite the generally high CD38 expression on most malignant plasma cells (PCs), variation in the surface level may affect the clinical efficacy of targeted therapy.4-9 Unfortunately, therapeutic anti-CD38 mAbs can interfere with detection and quantification of PC CD38 surface levels by conventional clinical flow cytometry (FC) assays for up to 6 months.10-12 Thus, the prevalence and course of CD38 antigen escape have not been well characterized.
%[ 11/15/2025
%U https://doi.org/10.1182/bloodadvances.2023011295